No Correlation between Beta2-Adrenergic Receptor Polymorphisms and the Severity and Clinical Control of Geriatric Asthma and COPD

Abstract

Background: Polymorphisms of the β2-adrenergic receptor (ADRB2) have previously been associated with non-specific bronchial hyper-responsiveness, adverse response to β2-agonists and variable effects on lung function. The objective of this study was to determine whether genotypic variance in ADRB2 polymorphisms in a cohort of geriatric men and women with asthma and/or COPD correlate with disease severity, baseline pulmonary function, and the ability to maintain clinical control of their disease.Methods: This comparative, prospective cohort study sequenced two ADRB2 polymorphisms, Arg16 --> Gly and Gln27 --> Glu, in 103 geriatric patients with a clinical history of asthma and/or COPD. Primary endpoints included pulmonary exacerbation rate, hospitalization rate, and quality of life scores.Results: Arg/Arg genotype comprised 13.6% of the cohort. No significant differences in baseline pulmonary functions were noted across genotypic variants. No significant difference was associated with genotype and change in lung function, exacerbations, clinical hospitalizations, exercise tolerance and subjective quality of life assessment over 6 months of follow-up. Conclusion:We conclude that in a geriatric asthma and/or COPD population, ADRB2 polymorphisms are not a factor in the ability to control disease.

ASSOCIATION OF THE ADRB2 GENE POLYMORPHIC VARIANT C79G (rs1072714) WITH THE COURSE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN OBESE AND NON-OBESE PATIENTS

“…Attention has been paid to studying the role of the sympathetic nervous system and the polymorphism of the β2-adrenoceptor genes in the development of chronic obstructive pulmonary disease in recent years, but the findings of the studies contradict each other (Thomsen et al, 2012;Randhawa et al, 2014). The aim of this study is to establish an association between the ADRB2 gene polymorphic variant C79G (rs1072714) in obese and non-obese COPD patients.…”